Aetna considers any of the following therapies medically necessary for the treatment of Guillain-Barre syndrome (GBS):
Aetna considers the use of any of the following therapies for the treatment of GBS experimental and investigational because their effectiveness for this indication has not been established (not an all-inclusive list).
Guillain-Barre syndrome (GBS) is an acquired acute peripheral neuropathy causing limb weakness that progresses over a period of days to weeks. It occurs with a median annual incidence of 1.3 cases per population of 100,000, with men being more frequently affected than women. The prognosis of GBS is generally favorable, but it is a serious disease with a mortality of about 10 % and approximately 20 % of patients are left with severe disability. Guillain-Barre syndrome is considered to be an autoimmune disease triggered by a preceding bacterial or viral infection. Campylobacter jejuni, cytomegalovirus, Epstein-Barr virus, and mycoplasma pneumoniae are commonly identified antecedent pathogens. It is a heterogeneous disorder representing at least 5 different entities -- 3 are predominantly motor; namely acute inflammatory demyelinating polyneuropathy (AIDP), acute motor sensory axonal neuropathy (AMSAN), and acute motor axonal neuropathy (AMAN); and the remaining 2 variants are Fisher syndrome, and acute panautonomic neuropathy (Lindenbaum et al, 2001; Kuwabara, 2004).
In the AMAN form of GBS, the infecting organisms probably share homologous epitopes to a component of the peripheral nerves and, therefore, the immune responses cross-react with the nerves causing axonal degeneration; the target molecules in AMAN are likely to be gangliosides GM1, GM1b, GD1a and GalNAc-GD1a expressed on the motor axolemma. In the AIDP form of GBS, immune system reactions against target epitopes in Schwann cells or myelin result in demyelination; however, the exact target molecules in the case of AIDP have not yet been identified. Acute inflammatory demyelinating polyneuropathy is by far the most common form of GBS in Europe and North America, whereas AMAN occurs more frequently in eastern Asia, namely China and Japan (Kuwabara, 2004).
Treatment of GBS entails management of severely paralyzed patients with intensive care and ventilatory support, and specific immunomodulating therapies that shorten the progressive course of GBS, presumably by limiting nerve damage. High-dose intravenous immunoglobulin (IVIG) and plasmapheresis (PP)/plasma exchange (PE)/therapeutic apheresis aid more rapid resolution of the disease. The predominant mechanisms by which IVIG exerts its action appear to be a combined effect of complement inactivation, neutralization of idiotypic antibodies, cytokine inhibition and saturation of Fc receptors on macrophages.
There is insufficient evidence that patients with GBS respond to corticosteroids (Lindenbaum et al, 2001; Czaplinski and Steck, 2004; Newswanger and Waren, 2004; Kuwabara, 2004). Furthermore, a Cochrane review on corticosteroids for GBS (Hughes et al, 2006) stated that limited evidence demonstrates that oral corticosteroids markedly slow recovery from GBS. Substantial evidence shows that intravenous methylprednisolone alone does not produce significant benefit or harm. The authors noted that further investigation is needed and more effective treatments for GBS should be sought.
In a multi-center, randomized controlled study (n = 233), van Koningsveld et al (2004) reported that there was no significant difference between methylprednisolone plus IVIG and IVIG alone in the treatment of patients with GBS. Odaka et al (2005) compared side effects in 9 patients with GBS treated with standard IVIG only and in 9 patients treated with combined methylprednisolone and IVIG therapy. Headache occurred in 2 patients in both groups, suggesting that pre-infusion with steroids does not prevent headache.
In a Cochrane review, Hughes and colleagues (2010) examined the effectiveness of corticosteroids in the teratment of GBS. These investigators searched the Cochrane Neuromuscular Disease Group Trials Specialized Register (June 2009), Medline (January 1966 to June 2009) and Embase from (January 1980 to June 2009). They included quasi-randomized or randomized controlled trials of any form of corticosteroid or adrenocorticotrophic hormone. The primary outcome was change in disability grade on a 7-point scale after 4 weeks of treatment; secondary outcomes included time from randomization until recovery of un-aided walking, time from randomization until discontinuation of ventilation (for those ventilated), death, death or disability (inability to walk without aid) after 12 months, relapse, and adverse events. Two authors extracted the data. No new trials were discovered in the new search in June 2009; 6 trials with 587 subjects provided data for the primary outcome. According to moderate quality evidence, the disability grade change following 4 weeks in the corticosteroid groups was not significantly different from that in the control groups, weighted mean difference (WMD) 0.36 less improvement (95 % confidence intervals [CI]: 0.16 more to 0.88 less improvement). In 4 trials of oral corticosteroids with 120 participants in total, there was significantly less improvement after 4 weeks with corticosteroids than without corticosteroids, WMD 0.82 disability grades less improvement, 95 % CI: 0.17 to 1.47). In 2 trials with a combined total of 467 participants, there was no significant difference, WMD 0.17 (95 % CI: -0.06 to 0.39) of a disability grade more improvement after 4 weeks with intravenous corticosteroids. According to moderate-to-high quality evidence, there were no significant differences between the corticosteroid-treated and the control groups in any of the secondary outcomes. Diabetes was significantly more common and hypertension significantly much less common in the corticosteroid-treated participants. The authors concluded that according to moderate quality evidence, corticosteroids given alone do not significantly hasten recovery from GBS or affect the long-term outcome. According to low quality evidence oral corticosteroids delay recovery. Diabetes requiring insulin was significantly more and hypertension less common with corticosteroids.
Interferon has not been shown to be effective for GBS. Pritchard et al (2003) performed a pilot double-blind, randomized, placebo-controlled safety trial of interferon beta 1a on patients with GBS. Participants received interferon beta 1a or placebo subcutaneously thrice-weekly, 22 ug for the first week and then 44 ug for up to 24 weeks, in addition to IVIG. These researchers reported that interferon beta 1a did not have any unexpected interaction with IVIG and there was no significant difference in rate of improvement.
Practice parameter on immunotherapy for GBS furnished by the Quality Standards Subcommittee of the American Academy of Neurology (Hughes et al, 2003) has the following recommendations:
Monaco and colleagues (2004) stated that in GBS and related variants, randomized clinical trials show that PE and IVIG are equally effective as disease-modifying treatments, although IVIG has been adopted as the favorite treatment in most centers. Finsterer (2005) stated that concerning the treatment of GBS, there is no significant difference between IVIG, PE, and PE followed by IVIG. Because of convenience and absent invasiveness, IVIG is usually preferred.
A Cochrane review (Hughes et al, 2006) stated that randomised trials in severe cases of GBS show that IVIG started within 2 weeks from onset hastens recovery as much as PE, which is known to be more effective than supportive care. Treatment with IVIG is significantly more likely to be completed than PE. Giving IVIG after PE did not confer significant extra benefit. In children, IVIG probably hastens recovery compared with supportive care alone. The authors stated that more research is needed in mild disease and in treatment starting more than 2 weeks following the onset of the condition. These findings are in agreement with the afore-mentioned recommendations of the American Academy of Neurology.
Raphael (2005) noted that PE is the first-line treatment for GBS. Two PE are recommended in patients who are able to walk (mild) with 2 additional PE if they deteriorate. In patients who are unable to walk without assistance (moderate), 4 PE are sufficient, likewise in those who require mechanical ventilation (severe form). It is not useful to add further PE in more severe disease or if there is no response. High-dose of IVIG (0.4 g/kg daily for 5 days) and PE are equally effective in the treatment of intermediate and severe forms of GBS. The choice between the 2 options depends on their respective contraindications and local availability.
Amantadine has not been proven effective for treatment of GBS. In a randomized, double-blind, placebo-controlled, cross-over trial (n = 80), Garssen et al (2006) examined the effect of amantadine on severe fatigue related to GBS. During the pre-treatment phase, all patients were monitored for 2 weeks. Only patients with severe fatigue, defined as a mean fatigue score of greater than or equal to 5.0 on the Fatigue Severity Scale (FSS), were included in this study. Primary outcome measure was improvement of at least 1 point on the FSS. Secondary outcome measures were impact of fatigue, anxiety and depression, handicap, as well as quality of life. A total of 80 patients were randomized, of whom 74 were included for analysis. Fatigue appeared to be reduced already during the pre-treatment phase (p = 0.05), probably due to increased attention provided to the patients. No significant differences in any of the primary and secondary outcome measures were found. These researchers concluded that amantadine was not superior to placebo.
A multi-disciplinary consensus group reviewed the published medical literature and made recommendations regarding supportive care of persons with GBS (Hughes et al, 2005). In the acute phase in bed-bound adult patients, the group recommended the use of heparin and graduated pressure stockings to prevent deep vein thrombosis, monitoring for blood pressure, pulse, autonomic disturbances, and respiratory failure, and the timely institution of artificial ventilation and tracheostomy. The group noted that pain management is difficult, but carbamazepine or gabapentin may help. The cautious use of narcotic analgesics may be needed. Disabled patients should be treated by a multi-disciplinary rehabilitation team and should receive an assistive exercise program. Persistent fatigue following GBS is common and may be helped by an exercise program. The group stated that, because of a very small and possibly only theoretical increase in the risk of recurrence following immunization, the need for immunization should be reviewed on an individual basis. The group reported that more research is needed to identify optimal methods for all aspects of supportive care.
van Doorn (2009) noted that epidemiological studies have shown that the incidence of GBS remains stable at about 2/100,000 per year; but that there have been changes in hospitalization use, likely due to the widespread availability of IVIG. Research into mechanisms has shown the importance of single amino acids in campylobacter jejuni and the importance of ganglioside conformation. In a murine model of anti-ganglioside antibody-mediated neuropathy, eculizumab was effective in reversing clinical disease and preventing pathology. This suggested trials of eculizumab in GBS should be considered. However, there are no new randomized controlled trials in GBS to report.
In a Cochrane review, Hughes et al (2011) reviewed systematically the evidence from randomized controlled trials for pharmacological agents other than PE, IVIG and corticosteroids. These investigators searched the Cochrane Neuromuscular Disease Group Specialized Register (July 5, 2010), the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2010, Issue 2), MEDLINE (January 1966 to June 2010) and EMBASE (January 1980 to June 2010) for treatments for GBS. They included all randomized or quasi-randomized controlled trials of acute (within 4 weeks from onset) GBS of all types, ages and degrees of severity; and discarded trials that only tested corticosteroids, IVIG or PE. These researchers included other pharmacological treatments or combinations of treatments compared with no treatment, placebo treatment or another treatment. Change in disability after 4 weeks was the primary outcome. Two authors checked references and extracted data independently. One author entered and another checked data in Review Manager (RevMan). They assessed risk of bias according to the Cochrane Handbook for Systematic Reviews of Interventions. They calculated mean differences and risk ratios with their 95 % CIs. They assessed strength of evidence with GradePro software. Only very low quality evidence was found for 4 different interventions. One randomized controlled trial with 13 participants showed no significant difference in any outcome between IFN beta-1a and placebo. Another with 10 participants showed no significant difference in any outcome between brain-derived neurotrophic factor and placebo. A third with 37 participants showed no significant difference in any outcome between cerebrospinal fluid filtration and PE. In a fourth with 20 participants, the risk ratio of improving by one or more disability grades after 8 weeks was significantly greater with the Chinese herbal medicine tripterygium polyglycoside than with corticosteroids (risk ratio 1.47; 95 % CI: 1.02 to 2.11). The authors concluded that the quality of the evidence was very low. Three small randomized controlled trials, of IFN beta-1a, brain-derived neurotrophic factor and cerebrospinal fluid filtration, showed no significant benefit or harm. A 4th small trial showed that the Chinese herbal medicine tripterygium polyglycoside hastened recovery significantly more than corticosteroids but this result needs confirmation. It was not possible to draw useful conclusions from the few observational studies.
In a Cochrane review, Liu and colleagues (2013) evaluated the safety and effectiveness of pharmacological treatments for various pain symptoms associated with GBS, during both the acute and convalescent (3 months or more after onset) phases of GBS. On August 27, 2012, these investigators searched the Cochrane Neuromuscular Disease Group Specialized Register, CENTRAL (2012, Issue 8) in The Cochrane Library, MEDLINE (January 1966 to August 2012) and EMBASE (January 1980 to August 2012). In addition, they searched ClinicalTrials.gov and the World Health Organization (WHO) International Clinical Trials Registry Platform. These researchers included randomized controlled trials (RCTs) and quasi-RCTs in participants with confirmed GBS, with pain assessment as either the primary or secondary outcome. For cross-over trials, an adequate washout period between phases was required for inclusion. Two review authors independently screened the titles and abstracts of identified records, selected studies for inclusion, extracted eligible data, cross-checked the data for accuracy and assessed the risk of bias of each study. A total of 3 short-term RCTs, which enrolled 277 randomized participants with acute phase GBS, were included. Risk of bias in the included studies was generally unclear due to insufficient information. None of the included studies reported the primary outcome selected for this review, which was number of patients with self-reported pain relief of 50 % or greater. One small study investigated 7-day regimens of gabapentin versus placebo. Pain was rated on a scale from 0 (no pain) to 10 (maximum pain). Among the 18 participants, significantly lower mean pain scores were found at the end-point (day 7) in the gabapentin phase compared to the end-point of the placebo phase (mean difference -3.61, 95 % CI: -4.12 to -3.10) (very low quality evidence). For adverse events, no significant differences were found in the incidence of nausea (risk ratio (RR) 0.50, 95 % CI: 0.05 to 5.04) or constipation (RR 0.14, 95 % CI: 0.01 to 2.54). A second study enrolling 36 participants compared gabapentin, carbamazepine and placebo, all administered over 7 days. Participants in the gabapentin group had significantly lower median pain scores on all treatment days in comparison to the placebo and carbamazepine groups (p < 0.05). There were no statistically significant differences in the median pain scores between the carbamazepine and placebo groups from day 1 to day 3, but from day 4 until the end of the study significantly lower median pain scores were noted in the carbamazepine group (p < 0.05) (very low quality evidence). There were no adverse effects of gabapentin or carbamazepine reported other than sedation. One large RCT (223 participants, all also treated with IVIG), compared a 5-day course of methylprednisolone with placebo and found no statistically significant differences in number of participants developing pain (RR 0.89, 95 % CI: 0.68 to 1.16), number of participants with decreased pain (RR 0.95, 95 % CI: 0.63 to 1.42) or number of participants with increased pain (RR 0.85, 95 % CI: 0.52 to 1.41) (low quality evidence). The study did not report whether there were any adverse events. The authors concluded that while management of pain in GBS is essential and pharmacotherapy is widely accepted as being an important component of treatment, this review did not provide sufficient evidence to support the use of any pharmacological intervention in people with pain in GBS. Although reductions in pain severity were found when comparing gabapentin and carbamazepine with placebo, the evidence was limited and its quality very low. They stated that larger, well-designed RCTs are needed to further investigate the safety and effectiveness of potential interventions for patients with pain in GBS. Additionally, interventions for pain in the convalescent phase of GBS should be investigated.
Pena et al (2014) noted that pain is a common symptom in patients with GBS. Intensity is moderate to severe in most cases and pain may persist after resolution of the disease. These researchers identified the most appropriate analgesic therapy for pain management in patients with GBS. They performed a systematic review and selection of scientific articles on treatment of pain in GBS patients, published between January 1985 and December 2012. They included only double-blind RCTs assessing the effectiveness of drugs for pain management in these patients. A total of 4 articles met the inclusion criteria. One evaluated the use of gabapentin, another evaluated carbamazepine, a third compared gabapentin to carbamazepine, and the last evaluated use of methylprednisolone. Both carbamazepine and gabapentin were useful for pain management. Patients experienced lower-intensity pain with gabapentin treatment in the study comparing that drug to carbamazepine. Methylprednisolone was not shown to be effective for reducing pain. The published data did not permit completion of a meta-analysis. The authors concluded that there is no robust evidence at present that would point to a single treatment option for this disorder. Moreover, they stated that further clinical studies of larger patient samples and with a longer duration are needed to characterize types of pain for each patient and measure pain intensity in an objective way.
Furthermore, an UpToDate review on “Treatment and prognosis of Guillain-Barré syndrome in adults” (Vriesendorp, 2014) states that “Aside from plasma exchange and intravenous immune globulin (IVIG), no other pharmacologic agents have been found to be effective for GBS. Interferon-beta has been reported to be beneficial in individual cases, but in a small randomized controlled trial, interferon-beta therapy was not associated with significant clinical improvement, and possible medication-related side effects were common”.
Tzachanis et al (2014) reported on the case of a 79-year old man with chronic lymphocytic leukemia who presented with GBS with features overlapping with the Miller Fisher syndrome and Bickerstaff brainstem encephalitis and positive anti-ganglioside GQ1b antibody about 6 months after treatment with bendamustine and rituximab. His clinical and neurologic condition continued to deteriorate despite sequential treatment with corticosteroids, IVIG and plasmapheresis, but in the end, he had a complete and durable response to treatment with alemtuzumab. The findings of this single-case study needs to be validated by well-designed studies.
Zhang et al (2014) stated that GBS is an immune-mediated acute inflammatory disorder of the peripheral nervous system (PNS) in humans characterized by inflammatory infiltration and damage to myelin and axon. Experimental autoimmune neuritis (EAN) is a useful animal model for studying the pathogenesis and treatment of GBS. Immunocompetent cells together with cytokines produced by various cells contribute to the inflammatory process of GBS and EAN by acting as mediators or effectors. Both GBS and EAN have long been attributed to T helper (Th) 1 cell-mediated autoimmune disorders. Interferon-gamma (IFN-γ) acts as a central mediator of Th1-mediated autoimmune disorders by deflecting the immune response toward a Th1 phenotype by inducing the differentiation of T cells to a Th1 phenotype and inhibiting the development of Th2 cells in autoimmune disorders such as GBS. These investigators presented an overview of current knowledge on the inflammatory and immune-regulatory role of IFN-γ in GBS and EAN, which is important for evaluating whether IFN-γ can become a potential therapeutic target in GBS. The authors concluded that analysis of immuno-pathogenesis of GBS and EAN revealed the significance of IFN-γ in both diseases, even though the complex mechanism of the delicate modulation of the cytokine is still under debate. They stated that more work is needed to rule out its potential in immune-regulatory function and pave the way for new therapeutic strategies for GBS.
|CPT Codes / HCPCS Codes / ICD-10 Codes|
|Information in the [brackets] below has been added for clarification purposes.  Codes requiring a 7th character are represented by "+":|
|ICD-10 codes will become effective as of October 1, 2015:|
|CPT codes covered if selection criteria are met:|
|36514||Therapeutic apheresis; for plasma pheresis|
|36515||with extracorporeal immunoadsorption and plasma reinfusion|
|90283||Immune globulin (IgIV), human, for intravenous use|
|HCPCS codes covered if selection criteria are met:|
|J1561||Injection, immune globulin, (Gamunex/Gamunex-C/Gammaked), nonlyophilized (e.g., liquid), 500 mg|
|J1566||Injection, immune globulin, intravenous, lyophilized, (e.g., powder), 500 mg|
|J1568||Injection, immune globulin, (Octagam), intravenous, nonlyophilized (e.g., liquid), 500 mg|
|J1569||Injection, immune globulin, (Gammagard liquid), nonlyophilized, (e.g., liquid), 500 mg|
|G0332||Services for intravenous infusion of immunoglobulin prior to administration (this service is to be billed in conjunction with administration of immunoglobulin)|
|S9473||Pulmonary rehabilitation program, non-physician provider, per diem|
|HCPCS codes not covered for indications listed in the CPB:|
|G9017||Amantadine HCl, oral, generic name, 100 mg (for use in a Medicare-approved demonstration project)|
|G9033||Amantadine HCl, oral, brand name, 100 mg (for use in Medicare-approved demonstration project)|
|J0702||Injection, betamethasone acetate and betamethasone sodium phosphate, per 3 mg|
|J1020||Injection, methylprednisolone acetate, 20 mg|
|J1030||Injection, methylprednisolone acetate, 40 mg|
|J1040||Injection, methylprednisolone acetate, 80 mg|
|J1094||Injection, dexamethasone acetate, 1 mg|
|J1100||Injection, dexamethasone sodium phosphate, 1 mg|
|J1300||Injection eculizumab 10 mg|
|J1700||Injection, hydrocortisone acetate, up to 25 mg (Hydrocortone acetate)|
|J1710||Injection, hydrocortisone sodium phosphate, up to 50 mg|
|J1720||Injection, hydrocortisone sodium succinate, up to 100 mg|
|J2650||Injection, prednisolone acetate, up to 1 ml|
|J2920||Injection, methylprednisolone sodium succinate, up to 40 mg|
|J2930||Injection, methylprednisolone sodium succinate, up to 125 mg|
|J3301||Injection, triamcinolone acetonide, per 10 mg|
|J3302||Injection, triamcinolone diacetate, per 5 mg|
|J3303||Injection, triamcinolone hexacetonide, per 5 mg|
|J7506||Prednisone, oral, per 5 mg|
|J7509||Methylprednisolone, oral, per 4 mg|
|J7510||Prednisolone, oral, per 5 mg|
|J8540||Dexamethasone, oral, 0.25 mg|
|J9010||Injection, alemtuzumab, 10 mg|
|J9212||Injection, interferon alfacon-1, recombinant, 1 mcg|
|J9213||Interferon alfa-2A, recombinant, 3 million units|
|J9214||Interferon alfa-2B, recombinant, 1 million units|
|J9215||Interferon alfa-N3, (human leukocyte derived), 250,000 IU|
|J9216||Interferon gamma-1B, 3 million units|
|Q3027||Injection, interferon beta-1a, 1 mcg for intramuscular use|
|S9559||Home injectable therapy, interferon, including administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drug and nursing visits coded separately), per diem|
|ICD-10 codes covered if selection criteria are met:|